[Hemochromatosis related Arthropathy]

Area of Science:

• Genetics and Molecular Biology
• Rheumatology
• Endocrinology

Background:

• Hemochromatosis is an autosomal recessive disorder caused by HFE gene mutations, leading to excessive iron absorption.
• It's a systemic disease affecting multiple organs, including the musculoskeletal system, liver, heart, and endocrine glands.
• Musculoskeletal manifestations include arthropathy (osteoarthritis, CPPD arthritis) and osteoporosis.

Purpose of the Study:

• To review the pathophysiology and clinical manifestations of hemochromatosis-related arthropathy.
• To discuss the current therapeutic approaches for hemochromatosis and their impact on musculoskeletal complications.

Main Methods:

• Literature review of studies on hemochromatosis, iron metabolism, and musculoskeletal manifestations.
• Analysis of the effects of standard hemochromatosis treatments on joint and bone health.

Main Results:

• HFE gene mutations increase gut iron absorption, causing systemic iron overload.
• Common MSK complications are osteoarthritis, particularly in MCP joints 2 and 3, and calcium pyrophosphate-associated arthritis.
• While phlebotomy and iron chelation improve systemic organ damage, they show minimal benefit for arthropathy and osteoporosis.

Conclusions:

• Hemochromatosis-related arthropathy and osteoporosis are significant MSK complications of iron overload.
• Current hemochromatosis therapies are insufficient for managing these bone and joint issues.
• MSK manifestations require management strategies similar to idiopathic osteoarthritis and pseudogout.